The idea of using radiation to treat degenerative joint disease is not new. German-speaking countries in particular have a long clinical tradition of using low-dose radiotherapy for osteoarthritis, benign joint pain, and even conditions such as Dupuytren’s contracture and plantar fasciitis. The biological rationale is that very low doses of ionizing radiation can modulate inflammation, dampening the activity of inflammatory immune cells and altering signaling pathways involving molecules such as cyclooxygenase-2, transforming growth factor-beta, and interleukin-10, without destroying tissue. What has been missing, however, is the kind of high-quality, placebo-controlled evidence that modern medicine demands. Most prior studies were observational, unblinded, or lacked a sham control group, leaving open the possibility that much of the reported benefit was simply expectation effect. The LoRD-KNeA trial was designed specifically to close that evidentiary gap.

The study enrolled 114 patients with primary knee osteoarthritis across multiple centers in South Korea, including Seoul National University Hospital, Samsung Medical Center, and SMG-SNU Boramae Medical Center. To enter the trial, participants had to be at least 50 years old and to report baseline walking pain scores between 50 and 90 on a 100-point scale, ensuring that everyone had substantial but not end-stage symptoms. Participants were then randomly assigned to one of three groups: a sham irradiation group that underwent the full appearance of treatment without actual radiation, a low-dose group receiving a total of 0.3 Gray delivered in six fractions, and a higher-dose group receiving a total of 3 Gray in six fractions. Both active regimens were given as a single course, meaning patients completed all six sessions in a short treatment series and then received no further radiation. The trial was registered as NCT05562271 on ClinicalTrials.gov and approved by Korea’s Ministry of Food and Drug Safety and the institutional review boards of each participating hospital.

The choice of endpoint reflects how difficult it is to measure pain relief objectively. The primary outcome was the responder rate at four months according to the OMERACT-OARSI criteria, a standardized definition developed jointly by the Outcome Measures in Rheumatology group and the Osteoarthritis Research Society International. A patient counts as a responder only if they achieve either a substantial improvement in pain or function or a more moderate improvement across several domains simultaneously. This composite approach guards against the trap of declaring success based on a single, easily inflated measure. Secondary outcomes included the WOMAC index, which quantifies pain, stiffness, and physical function; the visual analog scale for pain; the patient global assessment; blood-based inflammatory markers such as C-reactive protein and erythrocyte sedimentation rate; and a battery of magnetic resonance imaging parameters, including the volume transfer constant known as Ktrans and the Whole-Organ MRI Score, which track joint inflammation and structural change.

The headline result was unambiguous at the four-month mark. In the modified intention-to-treat analysis, 70.3 percent of patients who received 3 Gray met the OMERACT-OARSI responder criteria, compared with 41.7 percent of those who received sham irradiation, a difference that reached statistical significance with a p value of 0.021. In practical terms, roughly seven in ten patients in the higher-dose group experienced clinically meaningful improvement within four months of a single six-session course, against about four in ten in the placebo group. The lower dose of 0.3 Gray produced a responder rate of 58.3 percent, which, while numerically better than sham, did not reach statistical significance. The per-protocol analysis, which included only patients who completed treatment as assigned, showed a similar pattern, reinforcing confidence in the primary finding.

Yet the story becomes more complicated when the timeline is extended. The advantage of the 3 Gray group persisted at eight months, but by twelve months the difference between active treatment and sham was no longer statistically significant. In other words, the treatment effect was real but time-limited, gradually converging with the placebo response over the course of a year. This pattern matters enormously for how the therapy might be used in practice. If the benefit lasts roughly six to eight months, low-dose radiotherapy could function as a repeatable, non-pharmacological bridge, offering patients windows of relief without the gastrointestinal, cardiovascular, and renal risks associated with long-term nonsteroidal anti-inflammatory drug use, and without the needles and infection risks of repeated corticosteroid injections.

Perhaps the most sobering finding came from the secondary outcomes. Mean changes in the WOMAC subscales, visual analog scale scores, patient global assessment, inflammatory markers, and MRI-based parameters did not differ significantly among the three groups. The trial’s authors note that no distinct benefits were observed in these continuous clinical or imaging measures, even though the binary responder rate clearly favored the higher dose. This disconnect is a well-known phenomenon in osteoarthritis research: a patient can cross the threshold for a clinically meaningful response while the group averages shift only modestly, and structural imaging often lags far behind symptom change, if it changes at all. It also underscores that the mechanism of low-dose radiotherapy in degenerative disease remains incompletely understood, and that symptom modulation, rather than measurable alteration of joint biology on standard imaging, may be what patients are experiencing.

On the safety front, the trial delivered a reassuring verdict. No treatment-related toxicities were reported among patients receiving either active dose. This is consistent with the broader understanding of radiation biology at these exposure levels: 3 Gray in six fractions is a tiny fraction of the doses used in curative cancer radiotherapy, which often exceed 60 Gray, and it is delivered to a small, superficial field over the joint. The doses are comparable to what patients receive from a handful of diagnostic CT scans spread over several sessions, and the theoretical long-term carcinogenic risk at such exposures is considered very low, particularly in patients over 50. For a population in which long-term painkiller use carries well-documented risks, a treatment with no reported adverse effects in a controlled trial is noteworthy in its own right.

The trial’s design also offers a masterclass in placebo control for physical therapies. Sham irradiation is notoriously difficult to implement convincingly, because patients receiving real radiotherapy see the machine, hear its sounds, and feel the positioning procedures. By replicating the full ritual of treatment for the control group, the investigators ensured that the 41.7 percent responder rate in the sham arm genuinely reflects expectation and natural disease fluctuation. That the active 3 Gray arm beat this benchmark significantly is precisely what makes the result credible, and it explains why the authors emphasize that their findings demonstrate a treatment effect beyond an early placebo response.

What happens next will determine whether this century-old idea finally enters mainstream practice. The authors conclude that a single course of 3 Gray low-dose radiotherapy produced a significant short-term improvement in responder rates among patients with knee osteoarthritis, while calling for further investigation of the therapy as a conservative, non-pharmacological option for selected patients. Key questions remain: whether repeat courses can extend the benefit, which patient subgroups respond best, whether the lower 0.3 Gray regimen might work with a different fractionation schedule, and whether longer follow-up can clarify the durability of relief and any late effects. The trial was supported by a grant from Korea Hydro and Nuclear Power Company, which the authors state did not influence the design or interpretation of the study. For the millions of people whose aching knees limit every step, the message is cautiously hopeful: a brief, painless course of very low-dose radiation may buy several months of meaningful relief, and the scientific case for taking this approach seriously has never been stronger.

Subject of Research: Low-dose radiation therapy as a non-pharmacological treatment for knee osteoarthritis

Article Title: Single course low-dose radiation therapy in knee osteoarthritis (LoRD-KNeA): a randomized controlled trial

Article References: Single course low-dose radiation therapy in knee osteoarthritis (LoRD-KNeA): a randomized controlled trial. (n.d.). https://doi.org/10.1186/s12916-026-05287-9

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05287-9

Keywords: low-dose radiation therapy, knee osteoarthritis, randomized controlled trial, sham-controlled, radiotherapy, pain relief, OMERACT-OARSI, WOMAC, placebo response, non-pharmacological treatment, clinical trial, radiation oncology

The trial enrolled 292 patients with symptomatic knee osteoarthritis classified as Kellgren-Lawrence grade 0, 1 or 2 on X-ray, a scale that ranges from no definite visible disease to definite bone spurs with possible early narrowing of the joint space. Notably, even patients with grade 0 X-rays showed evidence of osteoarthritis on MRI, meaning the study captured disease at its earliest stages. Patients with advanced grade 3 and 4 disease were excluded, keeping the focus squarely on early to moderate disease. The participants were unusually young for an osteoarthritis study, with a median age of just 38 years, a detail that makes the long follow-up period particularly valuable for tracking how the disease evolves over decades of life.

Participants were randomly assigned at a single institution in Russia to one of two treatment arms. The control group received glucosamine and chondroitin, two widely used dietary supplements often prescribed for joint health. The experimental group received the same medications plus a course of low-dose radiation therapy totaling 4.5 Gray, delivered in 10 treatments using an orthovoltage machine that generates low-energy X-rays. That total dose is a small fraction of what is used to treat cancer, where curative regimens often exceed 40 to 60 Gray. The rationale for using radiation at such low doses rests on a well-documented biological phenomenon: while high doses kill cells, very low doses can suppress inflammatory signaling, modulating the chronic inflammation that drives cartilage breakdown in osteoarthritis.

The short-term results reinforced what earlier studies had suggested. Both groups reported less pain immediately after treatment, but only the radiation arm sustained that benefit over time. Patients who received radiation therapy also reported significantly greater and more durable improvements in physical function and quality of life than those treated with medication alone. Because osteoarthritis has no cure and conventional therapies such as exercise, weight management, medications and injections relieve symptoms without reliably slowing structural progression, a treatment that could alter the disease course would represent a genuine shift in the field.

The structural evidence came from MRI scans tracked for three years after treatment. At 12 months, imaging scores showed slight improvement among patients who received radiation therapy, while the medication-only group continued to worsen. The significant difference between the groups persisted throughout the follow-up period. This alignment between what patients felt and what the scanner saw is what makes the study stand out, according to study author Bobby (Nagendra) Koneru, MD, FASTRO, a radiation oncologist at Loyola University in Maywood, Illinois. In his view, the most compelling aspect is how the outcomes fit together: sustained improvement in pain and function, less joint deterioration on MRI, and years later, less disability and fewer knee replacements among patients with grade 2 disease.

The long-term outcomes came from regional health records examined over a median follow-up of 11.9 years. Across the entire study population, radiation therapy was associated with a statistically significant 67 percent lower adjusted hazard of government-certified disability due to knee osteoarthritis. Koneru emphasized that this endpoint reflects an independently certified consequence of knee disease rather than a subjective report, complementing the improvements seen in symptoms and imaging. Because disability certification in the Russian system involves an external government assessment, the finding is less vulnerable to the placebo effects that can inflate patient-reported outcomes in unblinded trials.

The most striking results emerged among the 78 patients with grade 2 disease, where osteoarthritis was established but not yet advanced. Disability developed in 31 percent of patients who received radiation therapy compared with 61 percent of those on medication alone, and knee replacement was performed in 14 percent versus 36 percent respectively. Both differences were statistically significant. Koneru suggested that grade 2 disease may represent a window in which osteoarthritis is present but extensive joint damage has not yet occurred, offering an opportunity to study whether treating inflammation earlier can change the longer course of the disease. Across the full study population, however, the difference in knee replacement rates did not reach statistical significance, a caveat the researchers acknowledged.

The study carries important limitations that temper enthusiasm. Participants knew whether they had received radiation, and the control group received medication rather than simulated radiation, leaving open the possibility that expectation effects contributed to the symptom improvements. The long-term outcomes and the grade 2 subgroup analyses were exploratory rather than pre-specified primary endpoints. Follow-up MRI data were incomplete, although the imaging readers were blinded to treatment assignment. The trial was also conducted at a single institution in Russia, and differences in health care delivery or access to knee replacement may limit how broadly the results apply to other populations and health systems.

Safety data were reassuring within the limits of the study design. No acute radiation reactions or cancers within the treated area were reported during follow-up. Low-dose radiation therapy has been used for decades in parts of Europe and increasingly in the United States to relieve pain from osteoarthritis and other noncancerous inflammatory conditions. Still, the study was not designed to quantify rare late effects or lifetime cancer risk, a particularly relevant question in a population with a median age of 38, and larger prospective studies will be needed to assess long-term safety alongside the durability of benefit.

Experts outside the study team see the findings as a reason to push the science forward rather than a reason to change practice immediately. Gopal K. Bajaj, MD, MBA, FASTRO, co-chair of ASTRO’s Functional Radiation Medicine Task Force and a radiation oncologist at Inova Schar Cancer Institute in Fairfax, Virginia, noted that osteoarthritis treatments can help patients feel better but that there is far less evidence they change what is happening inside the joint. What makes these findings interesting, he said, is that the patient-reported improvement was accompanied by a measurable difference on MRI, moving the question beyond pain relief alone, and the long-term disability data add another reason to test whether low-dose radiation can affect the course of early osteoarthritis in a larger, rigorously controlled trial. Koneru agreed, calling for a multicenter randomized trial using simulated radiation as the control, with prospectively defined imaging and long-term clinical endpoints and a focus on patients with grade 2 disease. If such a trial confirms these results, a therapy borrowed from the cancer clinic could become a disease-modifying option for one of the world’s most common causes of chronic pain and disability.

Subject of Research: Low-dose radiation therapy for knee osteoarthritis progression

Article Title: Low-dose radiation therapy may slow progression of knee osteoarthritis, long-term study indicates

Article References: Low-dose radiation therapy may slow progression of knee osteoarthritis, long-term study indicates. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: low-dose radiation therapy, knee osteoarthritis, randomized trial, cartilage deterioration, MRI imaging, disability prevention, knee replacement, inflammation, orthovoltage X-rays, ASTRO, Kellgren-Lawrence grade, disease-modifying treatment